Of these validated MAP biomarkers, four were previously reportedto predict psychosis in an independent human blood transcriptomeinvestigation (FBP1, ZNF821, TBC1D2 andSIN3A), one of which was previously labelled a genetic variantfor SCZ risk (FBP1). This evidence concerns the gene TBC1D2 and psychotic disorder.